Nyxoah (NASDAQ:NYXH) Posts Earnings Results, Beats Expectations By $0.04 EPS

Nyxoah (NASDAQ:NYXH) posted its quarterly earnings results on Thursday. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04, FiscalAI reports. Nyxoah had a negative return on equity of 178.90% and a negative net margin of 443.16%. The business had revenue of $10.39 million for the quarter, compared to analyst estimates of $11.00 million.

Here are the key takeaways from Nyxoah’s conference call:

• Nyxoah cut its 2026 revenue guidance to €33 million–€35 million, citing a U.S. launch ramp more in line with historical adoption patterns, despite strong sequential growth in the quarter.
• U.S. revenue rose 29% sequentially to €6.7 million, while the company trained 80 surgeons and activated 53 accounts in Q3; it plans to prioritize deeper utilization at existing accounts.
• The ACCCESS study met its primary efficacy and safety endpoints in patients with complete concentric collapse (CCC), and Nyxoah submitted an FDA supplement seeking to expand Genio’s U.S. indication to this group, which the company estimates represents about one in four patients evaluated for the therapy.
• Gross margin improved to 63.1% from 60.5% a year earlier, and the company reported a narrower operating loss. It also cited higher 2027 CMS facility reimbursement rates for Genio procedures.
• Cash and financial assets fell to €77.1 million at September 30 from €97.8 million at June 30, underscoring the company’s ongoing cash use as it invests in its commercial launch.

Nyxoah Stock Performance

NASDAQ:NYXH traded up $0.03 during midday trading on Friday, reaching $0.85. 262,088 shares of the company traded hands, compared to its average volume of 235,695. Nyxoah has a twelve month low of $0.80 and a twelve month high of $5.92. The firm has a market capitalization of $32.78 million, a price-to-earnings ratio of -0.43 and a beta of 1.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.38 and a quick ratio of 2.31. The company has a fifty day moving average price of $1.27 and a 200 day moving average price of $2.42.

Analyst Upgrades and Downgrades

NYXH has been the subject of several recent research reports. Oppenheimer set a $4.00 target price on shares of Nyxoah in a research note on Thursday, August 6th. Robert W. Baird set a $2.31 price target on shares of Nyxoah in a research report on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nyxoah in a report on Wednesday, August 19th. Raymond James Financial set a $3.00 price target on shares of Nyxoah in a report on Tuesday, October 27th. Finally, Wall Street Zen raised shares of Nyxoah from a “sell” rating to a “hold” rating in a research report on Saturday. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Nyxoah currently has an average rating of “Hold” and a consensus price target of $3.55.

Nyxoah Company Profile

Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA), a common sleep-related breathing disorder. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares trade on the Nasdaq under the symbol NYXH.

Nyxoah’s principal product is the Genio system, an implantable, rechargeable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to help maintain an open airway during sleep by stimulating the nerves that control the tongue and related upper-airway muscles.